Beatrice M C, Pfeiffer D R
Biochem J. 1981 Jan 15;194(1):71-7. doi: 10.1042/bj1940071.
The mechanism by which palmitoyl-CoA inhibits Ca2+ uptake in liver and heart mitochondria was examined. At a given concentration of palmitoyl-CoA, the extent of inhibition is inversely related to the concentration of the respiratory substrate succinate. Palmitoyl-CoA inhibition of uncoupler-stimulated respiration and respiration stimulated by ionophore-A23187-induced Ca2+ cycling is also relieved by high succinate concentrations. These effects of palmitoyl-CoA and succinate concentration are distinct from the increase in inner-membrane permeability, which can be produced by palmitoyl-CoA and Ca2+ [Beatrice, Palmer & Pfeiffer (1980) J. Biol. Chem. 255, 8663-8671]. The apparent K0.5 of the mitochondrial Ca2+ pump is not altered by palmitoyl-CoA. No or negligible effects of palmitoyl-CoA on the Ca2+-uptake rate are observed when ascorbate replaces succinate as an energy source. These findings, together with the known activity of palmitoyl-CoA as a competitive inhibitor of the dicarboxylate carrier [Morel, Lauquin, Lunardi, Duszynski & Vignais (1974) FEBS Lett. 39, 133-138], indicate that palmitoyl-CoA inhibits energy-linked Ca2+ transport by limiting the rate of electron transport through limitation of succinate entry into the mitochondria rather than by directly inhibiting the Ca2+ carrier.
研究了棕榈酰辅酶A抑制肝脏和心脏线粒体摄取Ca2+的机制。在给定的棕榈酰辅酶A浓度下,抑制程度与呼吸底物琥珀酸的浓度呈负相关。高浓度琥珀酸也可缓解棕榈酰辅酶A对解偶联剂刺激的呼吸以及离子载体A23187诱导的Ca2+循环所刺激的呼吸的抑制作用。棕榈酰辅酶A和琥珀酸浓度的这些效应不同于内膜通透性的增加,内膜通透性增加可由棕榈酰辅酶A和Ca2+引起[Beatrice、Palmer和Pfeiffer(1980年)《生物化学杂志》255,8663 - 8671]。线粒体Ca2+泵的表观K0.5不受棕榈酰辅酶A的影响。当抗坏血酸替代琥珀酸作为能量来源时,未观察到棕榈酰辅酶A对Ca2+摄取速率有影响或影响可忽略不计。这些发现,连同棕榈酰辅酶A作为二羧酸载体竞争性抑制剂的已知活性[Morel、Lauquin、Lunardi、Duszynski和Vignais(1974年)《欧洲生物化学学会联合会快报》39,133 - 138],表明棕榈酰辅酶A通过限制琥珀酸进入线粒体的速率来限制电子传递速率,从而抑制能量偶联的Ca2+转运,而不是直接抑制Ca2+载体。